-transparent.png){kind=logo}
The therapeutic efficacy of intralesional BCG (Bacillus Calmette-Guerin; one immunizing dose every 2 weeks for a minimum of five treatments) was studied in 19 melanoma patients. Of 15 patients evaluable for response, five experienced significant objective improvement (two complete and three partial remissions). Objective improvement was limited to those patients with dermal metastatic disease. In vitro cytotoxicity in the presence of patient's serum bore, on average, a relationship to the clinical disease. In certain individual cases, serum blocking and/or lymphocyte stimulation may have had prognostic significance.
Related Publications
M J Mastrangelo, and
H L Sulit, and
L M Prehn, and
R S Bornstein, and
J W Yarbro, and
R T Prehn
January 1976,
Neoplasma,
M J Mastrangelo, and
H L Sulit, and
L M Prehn, and
R S Bornstein, and
J W Yarbro, and
R T Prehn
January 1976,
Medical and pediatric oncology,
M J Mastrangelo, and
H L Sulit, and
L M Prehn, and
R S Bornstein, and
J W Yarbro, and
R T Prehn
October 1975,
Der Internist,
M J Mastrangelo, and
H L Sulit, and
L M Prehn, and
R S Bornstein, and
J W Yarbro, and
R T Prehn
June 1978,
Cancer,
M J Mastrangelo, and
H L Sulit, and
L M Prehn, and
R S Bornstein, and
J W Yarbro, and
R T Prehn
May 1976,
The Medical clinics of North America,
M J Mastrangelo, and
H L Sulit, and
L M Prehn, and
R S Bornstein, and
J W Yarbro, and
R T Prehn
February 1974,
Canadian Medical Association journal,
M J Mastrangelo, and
H L Sulit, and
L M Prehn, and
R S Bornstein, and
J W Yarbro, and
R T Prehn
October 1972,
Cancer chemotherapy reports,
M J Mastrangelo, and
H L Sulit, and
L M Prehn, and
R S Bornstein, and
J W Yarbro, and
R T Prehn
October 1975,
Cancer,
M J Mastrangelo, and
H L Sulit, and
L M Prehn, and
R S Bornstein, and
J W Yarbro, and
R T Prehn
December 2014,
Expert opinion on pharmacotherapy,
M J Mastrangelo, and
H L Sulit, and
L M Prehn, and
R S Bornstein, and
J W Yarbro, and
R T Prehn
July 2016,
Deutsche medizinische Wochenschrift (1946),
